Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys
Vijay brings more than 28 years of experience across healthcare, technology, edtech, manufacturing, and global business environments
Subscribe To Our Newsletter & Stay Updated
